DNTH 200
Alternative Names: DNTH-200Latest Information Update: 06 Oct 2022
At a glance
- Originator Dianthus Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action Complement system protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 04 Oct 2022 Early research in Autoimmune disorders in USA (Parenteral) (Dianthus Therapeutics pipeline, October 2022)